U.S. markets closed

Grifols, S.A. (GRF.MC)

MCE - MCE Precio retrasado. Divisa en EUR.
Añadir a la lista de seguimiento
9.11-0.04 (-0.46%)
Al cierre: 05:35PM CEST

Grifols, S.A.

Avinguda de la Generalitat, 152
Parc empresarial Can Sant Joan Sant Cugat del VallEs
Barcelona 08174
Spain
34 93 571 02 21
https://www.grifols.com

Sector(es)Healthcare
IndustriaDrug Manufacturers—General
Empleados a tiempo completo26,326

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. Thomas H. GlanzmannExec. Chairman150kN/D1958
Mr. Raimon Grifols RouraCo-CEO & Exec. Vice-Chairman1.04MN/D1964
Mr. Víctor Grifols DeuCo-CEO & Exec. Director1.04MN/D1977
Mr. Alfredo Arroyo GuerraCFO & VPN/DN/D1958
Mrs. Eva Bastida TubauCorp. VP and Director of Scientific & Medical AffairsN/DN/DN/D
Ms. Nuria Pascual LapeñaVP of Corp. Treasury, Risk Management Investor Relation & Sustainability OfficerN/DN/D1964
Mr. David Ian BellGen. Counsel & Chief Corp. Devel. OfficerN/DN/D1954
Mr. Mateo Florencio Borrás HumbertCorp. VP & Chief HR OfficerN/DN/D1956
Ms. Maria Teresa-Rioné LlanoChief Communications OfficerN/DN/D1965
Ms. Montserrat Gaja LlamasChief HR OfficerN/DN/D1965
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum–from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring–to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Gestión corporativa

La calificación ISS Governance QuickScore de Grifols, S.A. a partir del 30 de marzo de 2023 es 3. Las puntuaciones principales son Auditoría: 2; Junta: 5; Derechos del accionista: 7; Compensación: 4.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.